Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
Compounded Ketamine vs. Spravato: Two Different Paths to Treatment
If you're comparing compounded ketamine nasal spray cost vs Spravato, here's the direct answer: compounded ketamine, typically dispensed as sublingual troches, IV infusions, or IM injections, usually runs $250 to $700 per month out of pocket. Spravato (esketamine nasal spray) costs $590 to $885 per session at list price and can reach roughly $7,000 for a full acute treatment course before insurance. Both are ketamine-based options for treatment-resistant depression (TRD), a diagnosis for depression that has not improved after at least two adequate antidepressant trials, according to the National Institute of Mental Health. According to the World Health Organization, depression affects an estimated 280 million people worldwide, and a meaningful share do not respond fully to standard antidepressants, part of why faster-acting ketamine-based treatments have drawn attention. Spravato and compounded ketamine are not interchangeable products. They differ in molecular makeup, FDA approval status, evidence base, access requirements, and cost. This comparison breaks down each factor so you can weigh which path fits your clinical situation and budget. For background on how troches compare with other administration routes, see our troche vs. nasal spray guide.
Quick Answer
Compounded ketamine (troches, IV, or IM) typically costs $250 to $700 per month out of pocket and is rarely covered by insurance. Spravato costs $590 to $885 per session at list price, up to about $7,000 for a full induction course, though insurance with prior authorization can lower that substantially. Spravato is FDA-approved for treatment-resistant depression and requires administration at a certified facility with a 2-hour monitoring period. Compounded ketamine is prescribed off-label, and troches can be used at home.
Molecular Difference: Racemic Ketamine vs. S-Ketamine
Compounded ketamine contains racemic ketamine, a 50/50 mixture of two mirror-image molecules called enantiomers: R-ketamine and S-ketamine. R-ketamine is less potent at NMDA receptors, a type of glutamate receptor involved in mood regulation, but may contribute antidepressant effects through other pathways, including AMPA receptor modulation and mTOR pathway activation. S-ketamine is more potent at NMDA receptors, producing faster onset and greater dissociation per milligram. You can review the underlying molecular data in the PubChem compound summary.
Spravato contains only the S-enantiomer. Johnson & Johnson selected S-ketamine for Spravato because it is more potent and predictable, and because an enantiomerically pure formulation could be patented, something not possible with generic racemic ketamine. Some researchers, including work from Kenji Hashimoto's laboratory, have reported that R-ketamine may produce longer-lasting antidepressant effects than S-ketamine with less abuse potential, though this remains an active area of research and the clinical implications for patients are not fully resolved. For more on the compounded formulation used in troches, see our sublingual ketamine therapy guide.
Compare troche options
Compare troches with other ketamine routes and safety considerations.
Compare optionsFDA Approval and Regulatory Status
Spravato
The FDA approved Spravato in 2019 for treatment-resistant depression in adults and in 2020 for major depressive disorder with acute suicidal ideation or behavior. It is approved only alongside an oral antidepressant, not as a standalone treatment. Spravato is subject to a Risk Evaluation and Mitigation Strategy (REMS), FDA rules requiring administration in certified healthcare settings, and post-market surveillance data continues to accumulate.
Compounded Ketamine
Compounded ketamine is not FDA-approved as a psychiatric drug product. It is legal under 503A pharmacy compounding rules for individual prescriptions. Ketamine itself has been FDA-approved as an anesthetic since 1970; its use for depression is off-label. There is no REMS requirement and no mandatory treatment-setting restriction for troches, though individual prescribers set their own protocols. Learn more about how telehealth providers prescribe compounded ketamine troches.
FDA approval affects insurance coverage and regulatory certainty, and it means a product met specific safety and efficacy standards in controlled trials. It does not, on its own, prove superior efficacy over an off-label alternative.
Evidence Base: What the Research Shows
Spravato Clinical Trials
Spravato's approval rested on Phase 2 and Phase 3 randomized controlled trials, including the TRANSFORM-1, TRANSFORM-2, and TRANSFORM-3 trials for TRD and the ASPIRE-1 and ASPIRE-2 trials for MDD with suicidal ideation. These trials showed statistically significant improvement on the Montgomery-Asberg Depression Rating Scale (MADRS) compared with placebo, with TRANSFORM-2 serving as the pivotal study for the TRD approval. Several Spravato trials had mixed results and modest effect sizes in places, and the FDA advisory committee review was not unanimous.
Compounded Racemic Ketamine
IV racemic ketamine has been studied in dozens of trials over two decades, including landmark studies by Zarate et al. (2006) and Murrough et al. (2013). Meta-analyses consistently show rapid antidepressant effects, with effect sizes comparable to or exceeding those seen in Spravato trials. Sublingual and troche-specific data is less extensive but growing, supported by observational studies and some controlled work in outpatient settings. See our safety and efficacy comparison of esketamine and troches for more on this evidence gap.
Important
No published head-to-head randomized trial has directly compared IV racemic ketamine or troches with Spravato. Claims that one option is more effective than the other rely on indirect, cross-trial comparisons and should be treated with caution.
Cost Comparison
Spravato
Spravato is expensive at list price. A 56 mg dose (two devices) costs about $590 per session, and an 84 mg dose (three devices) costs about $885 per session. An acute phase of twice-weekly sessions for four weeks can run up to about $7,000 at list price, and maintenance dosing, once or twice monthly, typically costs $1,000 to $2,000 per month. Commercial insurance with prior authorization, plus manufacturer copay assistance, can reduce these costs substantially for some patients. Without insurance, Spravato is out of reach for most patients.
Compounded Ketamine (Troches)
Monthly troche therapy typically costs $150 to $400 for medication plus $100 to $300 in provider fees, totaling $250 to $700 per month, whether or not you have insurance, since insurance rarely covers compounded products. See our full breakdown of ketamine troche costs for a closer look. IV ketamine clinic sessions cost $400 to $800 each, so a six-session acute course runs $2,400 to $4,800. For patients without insurance coverage for Spravato, compounded ketamine is dramatically more affordable.
Administration and Access
Spravato
Spravato must be administered in a certified healthcare facility under REMS rules. The patient self-administers the nasal spray on site, then stays for a minimum two-hour monitoring period. Treatment requires a certified provider and a certified treatment center, and availability depends on the location of certified facilities. Patients cannot drive on treatment days.
Compounded Ketamine Troches
Troches can be prescribed by any licensed provider authorized to prescribe controlled substances and administered at home, with no mandatory facility monitoring period. This makes them accessible wherever a telehealth prescriber can practice and a compounding pharmacy can ship, with no facility certification requirement. For patients in rural areas or those with transportation limitations, compounded troches may be the only practically accessible ketamine-based option. Read more in our guide to ketamine troche options for treatment-resistant depression.
Insurance Coverage
Spravato
Spravato can be covered by commercial insurance, Medicare, or Medicaid for approved indications with prior authorization. Coverage criteria typically require documentation of two or more prior antidepressant treatment failures. Coverage is not guaranteed; prior authorization can be denied, and policies vary by insurer, so check with your insurer before starting treatment.
Compounded Ketamine
Insurance almost never covers compounded ketamine troches. As a non-FDA-approved compounded product, insurers typically classify it as experimental and exclude it from coverage. FSA and HSA funds may be usable for compounded ketamine expenses with appropriate documentation. For more on navigating these gaps, see our guide to the ketamine insurance coverage gap and patient assistance options.
Patient Experience Differences
Spravato's nasal administration causes discomfort, drip, or irritation for some patients, though the required two-hour facility stay provides a structured, monitored setting that some patients find reassuring. Troches are taken orally and dissolved under the tongue; some patients notice bitterness and find the dissolution process slow. Sessions run longer for troches, about two to three hours, compared with one to two hours for a Spravato visit, but the home setting allows for a more personalized environment.
Consider Spravato If
- You have insurance that covers it with prior authorization
- You want an FDA-approved treatment
- You have reliable access to a certified treatment facility
- You want a monitored, in-office administration setting
Consider Compounded Troches If
- You are paying out of pocket and cost is a primary concern
- You live far from a certified Spravato facility
- You prefer home-based, self-administered treatment
- A telehealth prescriber and compounding pharmacy are accessible to you
Many patients end up choosing based primarily on insurance coverage. If Spravato is covered and a certified facility is accessible, it is a reasonable first choice for TRD with a strong trial-based evidence record. If not, compounded ketamine, especially IV or troches, offers a clinically effective option with a longer track record in outpatient practice.
Steps Before You Decide
- Check with your insurer whether Spravato is covered and what prior authorization requires
- Ask a compounding pharmacy for current troche pricing and confirm it operates under 503A rules
- Confirm your prescriber's monitoring protocol for either treatment
- Compare total cost for a full induction course, not just the per-dose or per-session price
- Ask about distance to the nearest certified Spravato facility if you are considering that route
Key Takeaway
Spravato uses only the S-enantiomer of ketamine and is FDA-approved for TRD with required in-facility monitoring, while compounded ketamine, including troches, uses the racemic mixture and is prescribed off-label, often for home use. At list price Spravato costs far more than troches, but insurance coverage, when available, can reverse that gap for out-of-pocket cost.
Weighing side effects too?
Compare the side effect profile of troches with esketamine's nasal spray side effects before you commit to either treatment.
Learn More
Talk with a licensed provider to find out whether compounded ketamine troches fit your treatment goals and budget.
Frequently Asked Questions
No published head-to-head randomized trial has compared IV racemic ketamine or troches directly with Spravato. Indirect, cross-trial comparisons suggest racemic ketamine may produce comparable or larger effect sizes, but that evidence is not as strong as a direct trial would provide.
Rarely. Because compounded ketamine is not an FDA-approved psychiatric product, most insurers classify it as experimental and exclude it from coverage. Some patients use FSA or HSA funds for troche costs with appropriate documentation.
Spravato is a patented, FDA-approved brand-name drug that must be administered under a REMS program in a certified facility, which adds manufacturing, monitoring, and facility costs. Compounded ketamine troches are prepared by compounding pharmacies from generic ketamine and can be taken at home, which lowers overhead.
Some patients change routes if cost, access, or response is not working, but this decision should be made with your prescribing provider, since the two options have different monitoring requirements and dosing protocols.
Share
Related Reading
Contact Ketamine Troche
Send corrections, provider questions, or advertising inquiries.